Description

Listing of 1,89,62,247 equity shares of Artemis Medicare Services Limited issued on preferential basis pursuant to conversion of Compulsory Convertible Debentures, effective December 24, 2025.

Summary

BSE has announced the listing of 1,89,62,247 new equity shares of Artemis Medicare Services Limited (Scrip Code: 542919) effective December 24, 2025. These shares were issued at a premium of Rs.173.03 per share (face value Re.1) to non-promoters on a preferential basis pursuant to conversion of Compulsory Convertible Debentures (CCDs). The newly issued shares rank pari-passu with existing equity shares.

Key Points

  • Company: Artemis Medicare Services Limited
  • Scrip Code: 542919
  • Number of shares listed: 1,89,62,247 equity shares
  • Face value: Re. 1/- per share
  • Issue price: Rs. 174.03/- (Re. 1 face value + Rs. 173.03 premium)
  • Allotment to: Non-Promoters on preferential basis
  • Basis: Conversion of Compulsory Convertible Debentures (CCDs)
  • Distinctive Numbers: 139238251 to 158200497
  • ISIN: INE025R01021
  • Shares rank pari-passu with existing equity shares

Regulatory Changes

No regulatory changes announced in this circular.

Compliance Requirements

Trading members are informed to note the listing of these new securities for trading purposes effective December 24, 2025.

Important Dates

  • Date of Allotment: November 15, 2025
  • Listing/Trading Commencement Date: December 24, 2025
  • Notice Date: December 23, 2025

Impact Assessment

This is a routine listing notification following conversion of CCDs to equity shares. The addition of approximately 1.9 crore shares will increase the company’s equity capital and may result in dilution for existing shareholders. Impact is limited to Artemis Medicare Services Limited shareholders and investors. The preferential allotment to non-promoters indicates fresh capital infusion into the company.

Impact Justification

Routine listing notification for conversion of CCDs to equity shares on preferential basis. Standard corporate action with limited market-wide impact.